Thymosin alpha-1 as an adjunct to influenza vaccination improved antibody responses in elderly adults who typically have poor vaccine efficacy — addressing the age-related immune gap that makes elderly people vulnerable to flu.
Key findingThymosin alpha-1 as an influenza vaccine adjuvant improved seroconversion and antibody titers in elderly adults with normally impaired vaccine respons
What the researchers found
Thymosin alpha-1 as an influenza vaccine adjuvant improved seroconversion and antibody titers in elderly adults with normally impaired vaccine responses, addressing the immunosenescence that makes influenza vaccination less effective in the aged.
Why it matters
Relevant for thymosin-alpha-1, immune-function, anti-aging.
How the study worked
review study on thymosin-alpha-1, immune-function.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries.
Annals of the New York Academy of Sciences, 1112, 375-84
Citation
Ershler, William B; Gravenstein, Stefan; Geloo, Zeba S. (2007). Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries.. Annals of the New York Academy of Sciences, 1112, 375-84.